[Form 4] Pulse Biosciences, Inc Insider Trading Activity

Rhea-AI Filing Summary

Mahkam Zanganeh, a director of Pulse Biosciences (PLSE), reported receipt of two stock option grants on 08/15/2025 totaling 54,134 options. Both options have an exercise price of $16.16 and expire on 08/15/2035. The first option covers 30,000 shares and vests in equal monthly installments over one year beginning 09/15/2025. The second covers 24,134 shares and vests in equal quarterly installments over one year beginning 09/05/2025. Ownership after the transactions is reported as 30,000 and 24,134 shares respectively, held directly.

Positive

• Director award disclosed: The filing explicitly reports option grants to a company director, improving transparency.
• Clear vesting terms: Both grants include specific vesting schedules and first vesting dates, reducing ambiguity.
• Standard long term alignment: Options carry a 10‑year term and explicit exercise price of $16.16, aligning incentives over time.

Negative

• None.

Insights

Financial Analyst

TL;DR: Director received time‑based option grants totaling 54,134 shares at $16.16, standard ten‑year term.

The filing documents routine incentive compensation for a director rather than a market‑timed sale or purchase. The grants total 54,134 options with a $16.16 exercise price and 10‑year expiry, consistent with typical board award structures to align management and directors with shareholder interests. Vesting is time‑based over one year with specific first installment dates; no cash exercise or disposition was reported.

Corporate Governance Expert

TL;DR: These are standard service‑based option awards to a director with explicit monthly and quarterly vesting schedules.

The disclosure clearly states the nature, amounts, strike price, vesting cadence, and expiration dates. Because the awards are service‑conditioned and reported as direct ownership, they reflect compensation governance practice rather than an extraordinary corporate event. The filing is complete for the grant details provided.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zanganeh Mahkam

(Last) (First) (Middle)

601 BRICKELL KEY DRIVE

SUITE 1080

(Street)

MIAMI FL 33131

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PULSE BIOSCIENCES, INC. [ PLSE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$16.16	08/15/2025		A		30,000		(1)	08/15/2035	Common Stock	30,000	$0	30,000	D
Stock Option (right to buy)	$16.16	08/15/2025		A		24,134		(2)	08/15/2035	Common Stock	24,134	$0	24,134	D

Explanation of Responses:

1. The shares subject to the option will vest in equal monthly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 15, 2025.

2. The shares subject to the option will vest in equal quarterly installments over a one-year period, subject to the Reporting Person's continued service through each vesting date, with the first such installment occurring on September 5, 2025.

	/s/ Kenneth B. Stratton, as Attorney-in-Fact	08/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who filed the Form 4 for PLSE and what is their role?

Mahkam Zanganeh filed the Form 4 and is reported as a director of Pulse Biosciences.

What securities were granted to the reporting person on 08/15/2025?

Two stock options were granted totaling 54,134 options with an exercise price of $16.16.

What are the vesting schedules and first vesting dates for the options?

The 30,000‑option grant vests in equal monthly installments over one year beginning 09/15/2025; the 24,134‑option grant vests in equal quarterly installments over one year beginning 09/05/2025.

What are the exercise and expiration terms of the options?

Both options have an exercise price of $16.16 and an expiration date of 08/15/2035.

How many shares does the reporting person beneficially own after the transactions?

The filing reports 30,000 shares and 24,134 shares beneficially owned following the respective transactions, held directly.